Citalopram
- Generic Name
- Citalopram
- Brand Names
- Celexa, Ctp
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 59729-33-8
- Unique Ingredient Identifier
- 0DHU5B8D6V
- Background
Citalopram is an antidepressant belonging to the class of selective serotonin-reuptake inhibitors (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs. Citalopram enhances serotonergic transmission through the i...
- Indication
Citalopram is approved by the FDA for treating adults with major depressive disorder. It has also been used off-label to treat various diseases, including but not limited to sexual dysfunction, ethanol abuse, psychiatric conditions such as obsessive-compulsive disorder (OCD), social anxiety disorder, panic disorder, and diabetic neuropathy.
- Associated Conditions
- Alcohol Abuse, Anorexia Nervosa (AN), Binge Eating Disorder (BED), Bulimia Nervosa, Depression, Diabetic Neuropathies, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Separation Anxiety Disorder, Social Anxiety Disorder (SAD)
- Associated Therapies
- -
Microbiome of Depression & Treatment Response to Citalopram
- First Posted Date
- 2015-01-01
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 34
- Registration Number
- NCT02330068
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2016-03-14
- Target Recruit Count
- 3255526
- Registration Number
- NCT02320240
- Locations
- 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)
- Conditions
- Interventions
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 10
- Registration Number
- NCT02269540
- Locations
- 🇨🇦
Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- HolsboerMaschmeyer NeuroChemie GmbH
- Target Recruit Count
- 80
- Registration Number
- NCT02237937
- Locations
- 🇩🇪
Max Planck Institute of Psychiatry, Munich, Bavaria, Germany
Antidepressants and Bone Mineral Density
- Conditions
- Interventions
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Guiyang Medical University
- Target Recruit Count
- 203
- Registration Number
- NCT02179268
Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin
- Conditions
- Interventions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 40
- Registration Number
- NCT02092974
- Locations
- 🇩🇪
Charite Universitätsmedizin Berlin, Berlin, Germany
Brain Function and Structure in Cocaine Dependence
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 54
- Registration Number
- NCT02080832
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives
- Conditions
- Interventions
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT02028026
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 78
- Registration Number
- NCT02022709
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Neuroimaging Predictors of Antidepressant Treatment Outcome
- Conditions
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- University of Michigan
- Registration Number
- NCT02000726
- Locations
- 🇺🇸
Department of Psychiatry, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.